PP 29
Latest Information Update: 09 Jan 2008
At a glance
- Originator Hollis-Eden Pharmaceuticals
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cytomegalovirus infections
Most Recent Events
- 27 May 1999 New profile
- 27 May 1999 Preclinical development for Cytomegalovirus infections in USA (Unknown route)